Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 1.00 |
| ▸ | CHUK | O15111 | 3/20 | 0.77 |
| ▸ | RET | P07949 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.77 |
| ▸ | FLT4 | P35916 | 1/20 | 0.77 |
| ▸ | KDR | P35968 | 1/20 | 0.77 |
| ▸ | EPHB1 | P54762 | 1/20 | 0.77 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766982 | 0.89 | IKBKB (1.00) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2769663 | 0.89 | IKBKB (1.00) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL3043703 | 0.89 | IKBKB (1.00) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2768232 | 0.89 | IKBKB (0.85) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2766329 | 0.87 | IKBKB (1.00) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2766351 | 0.87 | IKBKB (0.80) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2768060 | 0.87 | IKBKB (1.00) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2767624 | 0.87 | IKBKB (1.00) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2768199 | 0.86 | IKBKB (0.83) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2765936 | 0.86 | IKBKB (0.89) | IKBKBCHUKRETCYP2C9EPHA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268855-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1888584-B1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | IKBKB 419/4885CHUK 1939/4885RET 803/4885 |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | IL1R1, IDO1, TLR1 | IKBKB 419/4885CHUK 1939/4885RET 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.